$1.240
-0.029 (-2.37%)At close
APVO News
APVO Events
Aptevo Therapeutics Presents New Data Showcasing Cancer Fighting Potential
Aptevo Therapeutics announced that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer, SITC, 2026 Annual Meeting. In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumors. Preclinical work also showed that APVO711 both activated immune cells and blocked a signal that weakens their response - showing potential to help the immune system fight solid tumors in two ways
Aptevo Announces Clinical Milestone for Mipletamig
Aptevo Therapeutics announced an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions, IRRs, following successive refinements to its priming-dose regimen. The improvement builds on mipletamig's already favorable safety and tolerability profile, including encouraging cytokine release syndrome, CRS, findings observed throughout its clinical development. Mipletamig data will be presented at the American Society of Hematology, ASH, 68th Annual Meeting in New Orleans, Louisiana from December 12-15, 2026. The ongoing RAINIER dose optimization study has demonstrated encouraging clinical activity and a favorable safety and tolerability profile for mipletamig, including favorable findings related to cytokine release syndrome. Building on these results, Aptevo has further improved tolerability through refinements to the priming-dose regimen, substantially reducing infusion-related reactions during initial treatment.
Aptevo Reports 10 Acute Myeloid Leukemia Patients Undergo Stem Cell Transplant
Aptevo Therapeutics announced that ten patients with newly diagnosed acute myeloid leukemia, AML, have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Stem cell transplant uses donor cells to replace a patient's blood-forming stem cells and can offer eligible patients the possibility of long-term remission or cure. Notably, ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. Mipletamig is being evaluated with venetoclax and azacitidine in RAINIER, Aptevo's Phase 1b/2 study in newly diagnosed AML patients who are not eligible for intensive induction chemotherapy.
Aptevo Advances Trispecific Therapy Programs, Expected to Enter Clinical Trials in 2027
Aptevo Therapeutics announced progress in its next-generation trispecific programs. The Company is optimizing several trispecific candidates for reliable, scalable manufacturing, an essential step toward future human testing. Aptevo expects to enter Investigational New Drug enabling studies for the lead candidate, APVO451, in 1H2027. Trispecific therapies are gaining attention across cancer drug development as researchers explore their potential to bring multiple complementary functions together in a single molecule. Trispecifics are engineered to do more than traditional antibody therapies. Each molecule can combine three complementary functions to recognize cancer, activate an immune attack and help overcome defenses that cancer uses to survive. Aptevo's protein-engineering and process development expertise makes it possible to bring these carefully selected functions together in one stable molecule and create differentiated therapies for specific cancers. "Trispecifics open an exciting new path in cancer drug development by allowing us to engineer several complementary functions into one therapy," said Peter Pavlik, PhD, Senior Director of Protein Engineering. "We are now taking the critical next step - optimizing trispecific candidates for reliable, scalable manufacturing, an essential step toward future human testing. Aptevo expects to enter Investigational New Drug-enabling studies for the lead candidate, APVO451, in 1H2027. This progress reflects both the strength of our engineering capabilities and our ability to translate promising science into potential medicines."
Aptevo Therapeutics Reports 93% Clinical Benefit Rate
Aptevo Therapeutics announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia - AML - patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment. Of 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 - 93% - experienced clinical benefit. Eleven patients achieved CR or CRi - 79% -, including nine complete remissions. These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed with the mipletamig triplet compares favorably with a published 41% composite remission rate for venetoclax plus azacitidine in treatment-naive patients with poor-risk cytogenetics and TP53-mutated AML. Currently, the RAINIER study is evaluating mipletamig in combination with venetoclax and azacitidine in frontline AML patients who are unfit to receive standard high-intensity chemotherapy in a dose optimization trial. This phase of the trial is expected to be completed by year-end, and regulatory interaction is planned for 1H27 to determine next steps.
Related articles
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.